APS Logo                                                                   FAll Meeting

APS presents: DIABETES, OBESITY and THE BRAIN

Friday, October 11, 2013
Marriott Crystal Gateway ~ Arlington, Virginia


 

The goals of this one-day meeting was to: provide an overview of current high-impact topics and active debates in the field of neural consequences of obesity, diabetes and their related complications; facilitate discussion among the participants; inspire new investigators; foster collaborations; and chart future directions for the field.

 

APS Program Chair, Dr. Sue Everson-Rose,
invites you to attend the 2013 'Diabetes, Obesity, and The Brain' meeting.


Agenda

8:00 am Breakfast

8:30-8:45 am Dr. Susan Lutgendorf, APS President and Dr. Susan Everson-Rose, Program Chair
Lutgendorf  Everson-Rose
Welcome

8:45-9:30 am Dr. Elizabeth Seaquist
Elizabeth Seaquist

Keynote: The Impact of Diabetes on Cerebral Structure and Function
Dr. Seaquist's presentation highlighted the clinical and public health importance of understanding how diabetes and obesity affect the brain, and showcased studies showing the effects of diabetes on brain metabolism, structure and function.

9:40-11:05 am Dr. Dianne F. Lattemann and Dr. Dana Small
Dianne F. Lattemann   Dana Small
Brain Systems of Feeding Behavior, Diabetes, and Obesity
This session presented an overview of the neural circuits that are involved in feeding behavior and reward, followed by an examination of how these circuits are affected by the nutrient environment and glucose metabolism.

11:15-12:15 pm Dr. Beatriz Luna and Dr. Antonio Convit
Beatriz Luna   Antonio Convit
Impact of Diabetes/Obesity on Cognitive Function in the Developing Brain
This session detailed the effects of metabolic dysregulation on brain structure and development, and provided perspective on how these pathways differ from healthy brain development in adolescence.

12:15-1:15 pm   Lunch

1:15-2:15 pm

Dr. Jose Luchsinger and Dr. Denise Park
Jose Luchsinger   Denise Park

Impact of Diabetes/Obesity on Cognitive Function in the Aging Brain
This session explored the effects of metabolic dysregulation on the brain and cognitive function in the context of disease and healthy aging.

2:25-3:55 pm Dr. John Gunstad, Dr. Andreana Haley and Dr. Bonnie Spring, moderator
John Gunstad Andreana Haley Bonnie Spring
DEBATE: Surgical Versus Non-Surgical Interventions for Diabetes and Obesity and Their Consequences for Cognition and Neurobehavioral Outcomes
The debate presented arguments in favor and against surgical and non-surgical interventions for obesity and diabetes, and their cognitive consequences.

3:55-4:15 pm   Walking Break

4:15-4:45 pm Dr. Robert Kaplan, OBSSR; Dr. Susan Czajkowski, NHLBI; Dr. Christine Hunter, NIDDK; Dr. Molly Wagster, NIA
Robert Kaplan  Susan Czajkowski Christine Hunter
NIH Funding Panel Discussion

4:45-7:00 pm Dr. Susan Everson-Rose and Dr. Elizabeth Seaquist
Susan Everson-Rose  Elizabeth Seaquist
Closing Remarks and Reception Dialogue
All speakers


Registration:
Registration is now closed.

Meeting Cancellation Policy     


Learning Objectives
Knowledge / Content Objectives:

  • Describe brain pathways that control food intake and reward and how they are altered by the food environment.
  • Explain how glucose metabolism influences reward processing.
  • Explain how the healthy brain develops and matures in adolescence and how metabolic disturbances affect this maturation process.
  • Describe the impact of obesity, diabetes, and metabolic dysregulation on neurobehavioral outcomes and cognition in people as they age.
  • Identify the pros and cons of surgical vs. non-surgical interventions for diabetes and obesity and their implications for brain adaptation and cognitive health.

Clinical Practice / Treatment Objectives:

  • Describe how models of neuroplasticity and cognitive aging can inform treatment of diabetes, obesity and metabolic syndrome.
  • Identify intervention components that derive from models of neuroplasticity and cognitive aging.
  • Recognize early brain vulnerability in patients.
  • Incorporate assessment of modifiable risk factors for cognitive decline into clinical practice.
  • Select appropriate treatment targets to preserve cognitive function in clinical settings.